Mach 1 Financial Group LLC Has $1.07 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mach 1 Financial Group LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 107.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,216 shares of the biopharmaceutical company’s stock after acquiring an additional 631 shares during the period. Mach 1 Financial Group LLC’s holdings in Regeneron Pharmaceuticals were worth $1,068,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $26,000. Fortitude Family Office LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. MCF Advisors LLC raised its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares in the last quarter. Criterion Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $37,000. Finally, Sutton Wealth Advisors Inc. grew its position in Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on REGN. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Finally, Bank of America lifted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $977.77.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. Insiders have sold a total of 10,195 shares of company stock valued at $9,759,898 over the last quarter. 8.83% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $1.82 on Tuesday, hitting $890.66. 627,942 shares of the company were exchanged, compared to its average volume of 491,369. The company’s 50 day moving average price is $945.77 and its two-hundred day moving average price is $895.19. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The firm has a market capitalization of $97.76 billion, a price-to-earnings ratio of 25.63, a PEG ratio of 2.54 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the previous year, the firm posted $10.96 EPS. The business’s revenue was up .6% compared to the same quarter last year. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.